Statin inhibitors, used to control hypercholesterolemia, trigger apoptosis of hematolological tumor cells and therefore have immediate potential as anti-cancer agents.
INTRODUCTION
Statins are a family of hydroxymethylglutaryl coenzyme A reductase (HMGCR) inhibitors commonly used to treat patients with hypercholesterolemia that are also known to induce apoptosis in a variety of tumor cells. To date, there are several lines of preclinical and epidemiological evidence to support the anti-cancer potential of statins. 1, 2 Some epidemiological analyses have demonstrated up to a 50% reduction in cancer risk among statin users [3] [4] [5] and partial or complete responses have been observed in some, but not all, patients undergoing early phase I/II trials. [6] [7] [8] [9] [10] [11] [12] These mixed responses underscore the importance of reliably identifying the appropriate subset of patients who stand to benefit most from statin-based anti-cancer therapy.
To ultimately advance statins as anti-cancer agents, it is therefore crucial to understand the molecular mechanisms involved in their anti-cancer activity and to delineate markers that distinguish the subset of tumors that are sensitive to statin-induced apoptosis.
Statin-induced apoptosis results directly from inhibiting HMGCR, the rate-limiting enzyme of the mevalonate (MVA) pathway. 2 The MVA pathway is a complex biochemical pathway required for the generation of several fundamental end-products including cholesterol, isoprenoids, dolichol, ubiquinone, and isopentenyladenine. 2, 13 Both HMGCR and the MVA pathway received considerable attention 20-30 years ago through the Nobel Prize winning efforts of Goldstein and Brown and the development of statins as blockbuster cholesterol-lowering drugs. This work defined how inhibition of HMGCR in non-transformed cells triggers a robust homeostatic feedback response that ensures the cells upregulate the MVA pathway. 13 Once statins have blocked HMGCR and depleted the intracellular end-products of the MVA pathway, cytoplasmic transcription factors known as sterol regulatory element binding proteins (SREBPs) are activated. 14 These transcription factors translocate to the nucleus, bind DNA at promoter
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From regions containing sterol response elements (SREs), and induce the transcription of several key target genes including HMGCR and the low-density lipoprotein receptor (LDLR). Upregulated LDLR on the cell surface then binds and internalizes extracellular LDL-laden cholesterol, thus reducing plasma cholesterol. It is this extraordinary feedback mechanism that has been successfully exploited to control hypercholesterolemia with statins. 15, 16 A tumor type that our lab and others have shown to be sensitive to statin-induced apoptosis is multiple myeloma (MM). [17] [18] [19] [20] [21] MM is a plasma cell malignancy with a median survival time of 5-10 years despite the use of high-dose chemotherapy and autologous stem cell transplants. 22, 23 As such, there is an urgent need for advances in both molecular diagnosis and treatments. Novel therapeutics are currently under investigation in MM but most, with the recent exceptions of bortezomib, thalidomide, and lenalidomide, have yet to show substantial efficacy and will require considerable pre-clinical and toxicity testing. Statins have an established track record for safety and statin-induced apoptosis is tumor-specific with limited collateral damage to non-transformed cells. 24, 25 These agents are therefore poised to make an immediate impact on cancer patient care. In our previous study, we determined that MM cell lines show a dichotomized response to lovastatin. 21 Of 17 MM cell lines assayed, approximately 50% were relatively sensitive to lovastatin-induced apoptosis while the rest were relatively insensitive.
This provided us with an ideal model system to further study the molecular determinants of statin sensitivity.
MATERIALS AND METHODS

Cell culture and compounds
All cell lines were assayed as asynchronously growing cells as described previously. 21 Lovastatin powder was a gift of Apotex Corp. (Mississauga, ON, Canada) and was activated and
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Ltd., East Sussex, UK) was dissolved in ethanol. 3-4,5-dimethylthiazolyl-2,2,5-diphenyl tetrazolium bromide (MTT) was purchased from Sigma (Mississauga, ON, Canada).
Array Data Pre-Processing
For each cell line analyzed by microarray (KMS11, H929, LP1, and SKMM1) three lovastatin-treated biological replicates and three vehicle (ethanol)-treated replicates were hybridized separately to Affymetrix U133 Plus 2.0 microarrays. The data was loaded into the R statistical environment (v2.7.2) using the affy package (v1.18.2) of the BioConductor opensource library. 26 All arrays showed minimal distributional or spatial heterogeneity. Array data was pre-processed using the gcrma algorithm, as implemented in the gcrma package (v2.12.1) of
BioConductor. 27 A custom, alternative CDF (hgu133plus2hsentrezgcdf, v11.0.0) was used to ensure an updated and one-to-one mapping of ProbeSets to Entrez Gene IDs. 28 Raw and preprocessed data have been deposited into the GEO database (accession GSE15946; reviewer link:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bziljueimeeyunw&acc=GSE15946).
Statistical Analysis
To identify genes significantly affected by lovastatin treatment we modeled the signal intensity of each ProbeSet as a linear sum of cell line effects and cell line-lovastatin interactions.
A contrast matrix was then used to identify the effects of lovastatin on each individual cell line.
This model was fit in the R statistical environment (v2.7.2) using the limma package (v2.14.7).
Coefficients and p-values were extracted, then subjected to an empirical Bayes moderation of standard error 29 and a false-discovery rate adjustment for multiple-testing.
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Downstream Analysis
Parameter sensitivity was assessed using p-value sensitivity analyses, where the number of differentially expressed genes was plotted as a function of the p-value threshold. Analysis was performed in the R statistical environment (v2.7.2) and visualization employed the lattice (v0. and latticeExtra (v0.5-3) packages using unsupervised machine-learning with multiple variance, signal-intensity, and F-statistic thresholds 30 . Genes were filtered by each threshold and their signal intensities subjected to divisive hierarchical clustering using the DIANA algorithm, as implemented in the cluster package (v1. and mapping them to Entrez Gene IDs by gene symbol. Pre-processed data was extracted for these genes, subjected to row-and column-jittering and divisive hierarchical clustering as described above. Pearson's correlation was used as a distance metric. Differential gene products in each cell line were subjected to GO ontological analysis using the GOMiner tool. 31 All human databases and all evidence codes were selected and 1000 permutations were used to estimate the null distributions. Categories with fewer than five genes were omitted from the analysis.
Analysis of cell line panel basal expression
We mined a publically available dataset that evaluated basal mRNA levels of 46 MM cell lines using Affymetrix U133A Plus 2.0 arrays. 32 Of the 46 cell lines, sensitivity to lovastatin was known for 16 (7 sensitive; 9 insensitive). Pre-processed data were associated with updated annotation using the Affymetrix NetAffx database (version na22). We trichotomized the set of cell lines into statin-sensitive, statin-insensitive, and unknown. Pair-wise comparisons between sensitive and insensitive groups were performed using t-tests with Welch's adjustment for
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Real-time PCR
Approximately 5 x 10 5 cells were seeded in 6-well tissue culture plates overnight and were either harvested directly or treated with ethanol (solvent control) or lovastatin at the concentrations and times described. RNA was harvested from cells using TRIZOL Reagent (Invitrogen) and cDNA was synthesized from 1 µg of RNA with SuperScript II (Invitrogen). Laemmli's loading dye was added at room temperature and samples were never boiled in order to limit the aggregation of membrane proteins. Blots were probed with anti-HMGCR (Cat. #07-572; Upstate), anti-tubulin (Santa Cruz), anti-actin (Sigma), or BCL2 (kindly provided by Dr.
Primers (Supplementary
David Andrews, Hamilton, ON).
Expression Vectors
Catalytic domain HMGCR cDNA was PCR-amplified from pHRed-102 (ATCC) with primers (Supplementary Table 1 Table 1 ) to remove nucleotides corresponding to exon 13 from cHMGCR-FL. All cloning was verified by sequencing. All retroviral particles, including pBabeMN-ires-GFP-BCL2, were produced and target cells infected as described previously. 21 Approximately equal levels of GFP positive cells were obtained after infection with all viral constructs as determined by flow cytometry (data not shown).
MTT and Fixed PI Assays
The MTT assays were conducted as previously described 25 except 5000 cells/well of a 96-well plate were plated and after 24 hours, cells were exposed to lovastatin (5 to 100 µM) for 48 hours. For fixed propidium iodide (PI) assays, 5 x 10 5 cells were seeded sub-confluently in 6-well tissue culture plates overnight. Cells were treated as indicated, harvested, washed in cold PBS, and fixed in cold 80% ethanol. They were stained with PI and analyzed using a 
Orthotopic MM model
Atorvastatin was evaluated in a previously described orthotopic model of MM. 33 Wholebody irradiated (2.5 Gy) 7-week old female non-obese diabetic severe combined immunodeficient (NOD/SCID) mice (Ontario Cancer Institute) were inoculated intravenously For early-stage disease treatment, dosing was initiated two days after KMS11-luc injection.
Atorvastatin, suspended in PBS, was administered 3 times a week for 37 days by oral gavage at 10 mg/kg and 50 mg/kg. Control mice received PBS alone. Tumors were imaged on designated days by whole-body imaging using the IVIS imaging system (Xenogen Corporation, Alameda, CA). Briefly, mice were injected intraperitoneally with luciferin (150 mg/kg, Caliper Life Sciences) followed by anesthetization with isoflurane. Twelve minutes post-luciferin injection gray-scale images followed by bioluminescent maps of the mice were obtained using a charge coupled device camera. Signal intensity was quantified using Living Image Version 2.50.2 (Xenogen) by summing detected photon counts from dorsal and ventral images. P-values were calculated using 1-way ANOVA followed by a Tukey's post test (P < 0.05 was considered significant). Survival curves (Kaplan-Meier survival analysis) were determined based upon the time at which mice were humanely euthanized after the onset of hind-limb paralysis due to tumor burden.
RESULTS
To better understand the determinants of sensitivity to statin-induced apoptosis, we exploited MM as a model system comprised of both sensitive and insensitive cell lines (detailed in 21 and summarized in Supplementary Figure 1 ). Microarray analysis was conducted to compare the mRNA levels of two sensitive (KMS11 and H929) and two insensitive (LP1 and SKMM1) MM cell lines. Cells were grown in the presence of 20 µM lovastatin or vehicle control for 16 hours, a time point that precedes the first indication of apoptosis in these cells and that is therefore useful for identifying mechanisms of action independent of general apoptosisrelated changes. 21 An unsupervised and unbiased clustering analysis indicated that global expression patterns of the sensitive cells were more similar to one another, in contrast to the insensitive cells ( Figure 1A ). Interestingly, one of the transcripts identified as being differentially regulated by statins (Supplementary Table 2 To determine whether the entire MVA pathway was dysregulated, we asked whether specific molecular pathways were differentially regulated in sensitive and insensitive MM cells (Table 1 and Supplementary Table 3) . Using GO pathway analysis, no pathways were found to be enriched for differentially regulated genes after lovastatin exposure in both sensitive cell lines.
In contrast, 22 GO pathways were identified as significantly enriched in both insensitive MM cell lines. Notably, the GO terms for cholesterol, sterol, steroid, and isoprenoid metabolic and biosynthetic processes were all enriched, supporting the notion that a dysregulated MVA An array technology developed to discover alternatively spliced transcripts recently identified a novel human splice variant of HMGCR. 34 The splicing event leads to the loss of Figure 2C ). One apparent exception to the pattern was the OCIMY5 cell line which, while insensitive to lovastatin-induced apoptosis, did not upregulate expression of HMGCR transcripts in response to the drug. This cell line was able to upregulate expression at the protein level ( Figure 1E ) and so appears to have developed a different mechanism to achieve the same result. Taken together, these data suggest that sensitive MM cells are unable to respond to statin exposure and it is potentially this difference that ultimately results in the cells undergoing apoptosis.
We next asked whether modulating expression of either HMGCR-FL or HMGCR-D13
could affect sensitivity to lovastatin-induced apoptosis. To date, studies of human HMGCR have been greatly limited by the lack of a successful overexpression strategy. As our own attempts to express the full-length protein have been similarly unsuccessful, we endeavored to overcome this challenge by expressing the catalytic region in the absence of its transmembrane domain that is known to harbor negative regulatory elements. 35 We therefore expressed catalytic domains of the two splice variants (cHMGCR-FL and cHMGCR-D13; Figure 3A Figure 3C ) and, in all cases, protein expression of the cHMGCR-FL construct was higher than cHMGCR-D13. Cells were then exposed to increasing concentrations of lovastatin and the antiproliferative effect was measured by MTT assay ( Figure   3D ). Interestingly, we determined that the sensitive KMS11 cells expressing cHMGCR-FL had been rendered less sensitive than the parental cells and the MTT 50 , the concentration required to reduce viability of the population by 50%, doubled from approximately 5 µM to 10 µM. No change in sensitivity was observed in KMS11 cells expressing cHMGCR-D13. Additionally, no changes in statin response were evident in insensitive LP1 cells expressing the ectopic cHMGCR constructs (data not shown).
As MTT assays measure the activity of a mitochondrial enzyme, it is not clear whether a decrease in metabolism of the MTT substrate is indicative of growth arrest, apoptosis, or senescence. As our previous work has indicated that sensitive MM cells undergo apoptosis in response to lovastatin 21 we performed fixed PI ( Figure 3E ) analysis as an assay for cell death after lovastatin exposure. In agreement with our MTT results, we showed that KMS11 cells expressing cHMGCR-FL, but not cHMGCR-D13, were less sensitive to statin-induced killing (left). This increase in resistance to lovastatin was specific as no added protection was conferred when cells were exposed to melphalan (middle) or bortezomib (right), two agents presently used in the management of MM. BCL2 was included as a positive control able to inhibit apoptosis induced by all agents.
While it could be possible to exploit an expression regulatory defect as a biomarker of statin sensitivity, a difference that can be observed at the basal level would be more clinically tractable. As our array analysis had indicated dysregulation of the MVA pathway at large ( Figure 1 and Table 1 ) we extended our study to include other sterol-regulated gene products.
To this end we mined a publically available dataset containing basal mRNA expression of a large panel of MM cell lines assayed using Affymetrix microarrays. 32 Many of the cell lines included in this panel had been previously characterized for their sensitivity to statin-induced apoptosis so we asked whether a subset of sterol-responsive genes were expressed differentially in sensitive cells compared to insensitive cells. We then evaluated the log 2 -fold differences between these subsets of MM cells ( Figure 4A ) as well as the statistical significance of these differences ( Figure 4B ). Interestingly, one of the most significant differentially expressed gene products was HMGCS1, the enzyme immediately upstream of HMGCR in the MVA pathway. It is also important to note that while our previous array experiment ( Figure 1 ) was not sufficiently powered to detect significant differences in expression at the basal level, we did see reproducibly higher basal HMGCR and HMGCS1 expression by real-time PCR ( Figure 1C , 1D, 2B, and 2C).
To validate this basal difference, we harvested mRNA from representative sensitive and insensitive MM cells and determined the basal expression of HMGCS1 ( Figure 4C ). LDLR was assayed as a negative control that did not appear to be differentially expressed in sensitive and insensitive MM cells ( Figure 4A , B, and D). Indeed, while HMGCS1 was found to be expressed more highly in insensitive MM cells, LDLR expression was considerably more variable.
To resolve how the regulation of HMGCS1 expression compared to that of HMGCR, we To establish whether these differences in expression could be extended to predicting the patients that might benefit from using statins as anti-cancer agents, we conducted a series of primary MM cell experiments. Over the span of several months, a sufficient number of myeloma cells were obtained from the bone marrow of 5 patients. These primary cells were exposed to 20 µM lovastatin, 20 µM atorvastatin, or a vehicle control. Atorvastatin was included in these experiments because it is expected to have better performance in vivo due to both a higher plasma half life and higher physiologically achievable concentrations. Following incubation for 16 hours, patient material was sorted for the CD138+ (MM cell) population and harvested for mRNA expression analysis. The remainder was incubated with drug for a total of 48 hours prior to being labeled for both CD138 and annexin V, to assess the percent of viable myeloma cells by flow cytometry ( Figure 6A ). Two samples were identified as modestly sensitive with 8-40% reductions in the CD138 positive population and a reciprocal increase in annexin V positive cells compared to vehicle control. The other three samples were insensitive to statin-induced apoptosis as MM cell viability remained relatively unchanged in response to statin exposure. Interestingly, primary patient cells that were insensitive to statin-induced apoptosis also showed higher HMGCR mRNA levels, both basally and as induced by the statins ( Figure 6B) . A differential was not as readily observed for HMGCS1 expression, possibly due to the small sample size. Taken together, these data suggest that expression of MVA pathway genes may identify a subset of patients with statin-sensitive tumors.
For
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Finally, to demonstrate that the efficacy of statins observed in tissue culture with cell lines or primary cells can be recapitulated in vivo, we employed an orthotopic murine model of MM. Sublethally irradiated NOD/SCID mice were intravenously injected with a sensitive cell line, KMS11, ectopically expressing luciferase. When subsequently injected with luciferin, the bioluminescent myeloma cells in these animals can be imaged and quantified. Importantly, the MM cells in this model colonize the bone marrow, a key feature of human disease. 33 These animals received 10 or 50 mg/kg of atorvastatin or a PBS vehicle control by oral gavage three times a week for 37 days, until the tumor bioluminescence in the control mice saturated the detectors. Impressively, tumor growth in the animals receiving atorvastatin was significantly lower than the control mice ( Figure 7A and B) and there were no overt signs of toxicity in the statin-treated mice. The groups receiving 10 or 50 mg/kg atorvastatin were essentially indistinguishable, suggesting statin efficacy was maximized. After treatments ceased, survival of the animals was monitored over time. All mice that received PBS were sacrificed before any of the statin-treated mice showed significant signs of disease ( Figure 7C ). These results show that anti-cancer statin therapy was both safe and effective in an in vivo model of myeloma using cells that display a dysregulated mevalonate pathway (Figures 1, 2 , and 5), a characteristic that we conclude is a determinant of statin sensitivity.
DISCUSSION
It is critical to reliably identify subsets of patients who can benefit from anti-cancer statin therapy. To attain this goal we need to better understand the molecular mechanisms of statininduced apoptosis and delineate specific determinants of sensitivity. It is well known that statins trigger tumor-specific apoptosis by inhibiting HMGCR, the rate-limiting enzyme of the MVA pathway. 2 For many years it was believed that the anti-cancer activity of statins was mediated by The results presented in this paper suggest that a key element of tumor cell sensitivity to statin-induced apoptosis lies in the feedback regulation of the MVA pathway. Our microarray data revealed that lovastatin exposure did not induce the expected feedback response in statinsensitive MM cells, although this response was intact in statin-insensitive cells ( Figure 1 and Table 1 ). We hypothesize this deficiency in upregulating MVA pathway gene products, such as HMGCR (Figure 2 ), ultimately leads to tumor cell death. It is also of particular note that cholesterol metabolism genes have been previously linked to drug resistance in MM. 37 This subset of genes, including HMGCR, was shown to be significantly increased in cells that had acquired drug resistance by either cell-adhesion or selection. These results suggested that cholesterol biosynthesis, and HMGCR especially, may play a fundamental role is mediating both de novo and acquired drug resistance.
Further analysis of a publically available microarray dataset revealed that certain genes of the sterol response pathway are differentially expressed in statin-sensitive MM cells compared to insensitive cells at a basal level (Figure 4) . Cumulatively, these differences have the potential to serve as statin-sensitivity determinants in MM and possibly other tumors. While HMGCR and HMGCS1 are both sterol-responsive genes with SRE transcriptional regions within their Figure 5B ). In fact, its variable expression suggests that LDLR regulation could be more universally aberrant, an observation that has been made in both AML and prostate cancer previously. [43] [44] [45] It was also recently reported that MM patients generally present with hypocholesterolemia. 46 When taken together one could speculate that this may be a consequence of dysregulated LDLR expression in myeloma cells, resulting in increased clearance of LDL-cholesterol in those patients. Experimental validation of this hypothesis will be required to determine if a differential exists between MM cells and normal cells that can be exploited in biomarker discovery and therapeutic targeting.
A novel splice variant of HMGCR, HMGCR-D13, has not yet been fully characterized.
While it has been shown to be widely expressed in a panel of normal tissues, 34 little is known about the role and regulation of HMGCR-D13 in human cancer. Interestingly, direct evidence has shown that a SNP (rs3846662) in intron 13 regulates the alternative splicing of HMGCR. 47 HMGCR-D13 has also recently been associated with a decreased cholesterol-lowering response in lymphocytes exposed to simvastatin. 48 Differential expression of HMGCR-FL and -D13 may impact both tumor etiology and statin sensitivity, and thus it will be critical to further evaluate.
If HMGCR-D13 has enzymatic activity refractory to statin inhibition, it would predict that
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cancers that elevate its expression will also be refractory to statins. Conversely, loss of HMGCR-D13 could sensitize cells to the anti-proliferative activity of statins.
In the present study, we monitored expression of both HMGCR-FL and -D13. While HMGCR-FL mRNA levels are about 10-fold higher than HMGCR-D13, they are both upregulated 2-4 fold in response to lovastatin exposure and largely appear to be co-regulated (Figure 2) . Furthermore, ectopic expression cHMGCR-FL, but not cHMGCR-D13, decreased lovastatin-induced apoptosis of sensitive MM cells. The decreased sensitivity conferred by cHMGCR-FL was statin-specific as cells exposed to melphalan and bortezomib, agents commonly used in the clinical management of MM, did not display a differential in sensitivity.
Cells expressing the cHMGCR-D13 construct were just as sensitive to statin-induced apoptosis as cells expressing the empty vector ( Figure 3C and D) , however, it is possible that this was due to the expression of cHMGCR-D13 being considerably lower than that of cHMGCR-FL.
Because control elements would be identical within each vector, this expression difference suggests that cHMGCR-FL could be more stable than cHMGCR-D13. This observation could have interesting implications on the nature and regulation of a cell's total HMGCR activity and warrants future investigation comparing the two isoforms. Nonetheless, our results do agree with one of the few previous studies on HMGCR-D13 in which HMGCR-D13 was unable to restore HMGCR activity when expressed in an HMGCR-deficient CHO cell line. 47 Taken together, our data suggest that while the expression of HMGCR-D13 may have diagnostic or prognostic potential as a determinant of statin sensitivity, it does not appear to have enzymatic activity equivalent to HMGCR-FL. More thorough analyses to elucidate the relative role and regulation of HMGCR-D13, how it compares to HMGCR-FL, and how it can impact patient prognosis and treatment will be of great interest in the future.
Our results show that normal feedback regulation of the MVA pathway is compromised in a subset of MM tumors. In non-transformed cells this feedback response allows statins to work as cholesterol-lowering agents. It may be this very same feedback response that also prevents a cell, normal or statin-insensitive tumor, from undergoing statin-induced apoptosis.
Formulated from the results of tissue culture experiments, this model was further supported by our analysis of primary patient cells (Figure 6 ). Interestingly, deficient feedback control or increased expression and activity of HMGCR have been reported in some tumors. 49, 50 While these observations suggest a more global dysregulation of the pathway occurs in cancer, our work has shown that there are likely unique subsets of tumors with dysregulated MVA pathways.
In fact, dysregulation of the mevalonate pathway provides a molecular rationale for the significant therapeutic index of statins observed in sensitive tumor cells. When we specifically targeted such sensitive cells in an orthotopic murine model of MM we demonstrated that statin therapy can be very effective and well tolerated ( Figure 7 ). While it should be noted that statins will likely be more effective when combined with other agents, the importance of selecting an appropriate group of patients to treat will be critical to the successful use of statins as anti-cancer agents. Ultimately, dysregulation of the MVA pathway may lead to the identification of an experimentally tractable biomarker that could be used to distinguish patients who would benefit most from the inclusion of statins in their anti-cancer regimens. 
